Telesis Bio Performance
| TBIODelisted Stock | USD 2.98 0.02 0.67% |
Telesis Bio holds a performance score of 7 on a scale of zero to a hundred. The entity has a beta of -1.55, which indicates a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Telesis Bio are expected to decrease by larger amounts. On the other hand, during market turmoil, Telesis Bio is expected to outperform it. Use Telesis Bio expected short fall, and the relationship between the maximum drawdown and rate of daily change , to analyze future returns on Telesis Bio.
Risk-Adjusted Performance
7 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Telesis Bio are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of very uncertain forward indicators, Telesis Bio displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 30.6 M |
Telesis |
Telesis Bio Relative Risk vs. Return Landscape
If you would invest 340.00 in Telesis Bio on August 25, 2024 and sell it today you would lose (42.00) from holding Telesis Bio or give up 12.35% of portfolio value over 90 days. Telesis Bio is currently generating 2.8271% in daily expected returns and assumes 29.2127% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Telesis, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Telesis Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Telesis Bio's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Telesis Bio, and traders can use it to determine the average amount a Telesis Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0968
| Best Portfolio | Best Equity | |||
| Good Returns | TBIO | |||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 29.21 actual daily | 96 96% of assets are less volatile |
Expected Return
| 2.83 actual daily | 56 56% of assets have lower returns |
Risk-Adjusted Return
| 0.1 actual daily | 7 93% of assets perform better |
Based on monthly moving average Telesis Bio is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Telesis Bio by adding it to a well-diversified portfolio.
Telesis Bio Fundamentals Growth
Telesis Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Telesis Bio, and Telesis Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Telesis Pink Sheet performance.
| Return On Equity | -1.48 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (2.53) % | ||||
| Operating Margin | (6.76) % | ||||
| Current Valuation | 61.1 M | ||||
| Shares Outstanding | 1.77 M | ||||
| Price To Earning | 71.32 X | ||||
| Price To Book | 1.11 X | ||||
| Price To Sales | 0.29 X | ||||
| Revenue | 27.51 M | ||||
| EBITDA | (31.05 M) | ||||
| Cash And Equivalents | 654.75 M | ||||
| Cash Per Share | 8.70 X | ||||
| Total Debt | 34.38 M | ||||
| Debt To Equity | 0.16 % | ||||
| Book Value Per Share | (11.59) X | ||||
| Cash Flow From Operations | (34.67 M) | ||||
| Earnings Per Share | (30.42) X | ||||
| Total Asset | 70.41 M | ||||
| Retained Earnings | (161.47 M) | ||||
| Current Asset | 3.28 M | ||||
| Current Liabilities | 16.98 M | ||||
About Telesis Bio Performance
By examining Telesis Bio's fundamental ratios, stakeholders can obtain critical insights into Telesis Bio's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Telesis Bio is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Translate Bio, Inc., a clinical-stage messenger RNA therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company was founded in 2011 and is headquartered in Lexington, Massachusetts. Translate Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 122 people.Things to note about Telesis Bio performance evaluation
Checking the ongoing alerts about Telesis Bio for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Telesis Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Telesis Bio is not yet fully synchronised with the market data | |
| Telesis Bio is way too risky over 90 days horizon | |
| Telesis Bio appears to be risky and price may revert if volatility continues | |
| Telesis Bio has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 27.51 M. Net Loss for the year was (47.72 M) with profit before overhead, payroll, taxes, and interest of 15.6 M. | |
| Telesis Bio currently holds about 654.75 M in cash with (34.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.7, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 38.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Telesis Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Telesis Bio's stock is overvalued or undervalued compared to its peers.
- Examining Telesis Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Telesis Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Telesis Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Telesis Bio's pink sheet. These opinions can provide insight into Telesis Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Other Consideration for investing in Telesis Pink Sheet
If you are still planning to invest in Telesis Bio check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Telesis Bio's history and understand the potential risks before investing.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Stocks Directory Find actively traded stocks across global markets | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |